Related Experiment Video

Updated: Jun 23, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

[Effect of small interfering RNA targeting CXCR4 on breast cancer angiogenesis]

Hong-yuan Li1, Guo-sheng Ren, Jin-xiang Tan

  • 1Department of General Surgery, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China. hongy_li@hotmail.com

Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University
|May 23, 2009
PubMed
Abstract

Insights

Small interfering RNA targeting CXCR-4 (shRNA-CXCR4) effectively reduced breast cancer cell angiogenesis. This gene silencing inhibited human umbilical vein endothelial cell tube formation, impacting tumor growth potential.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cell Biology

Context:

  • CXCR-4 is a chemokine receptor implicated in cancer progression.
  • Angiogenesis is crucial for tumor growth and metastasis.
  • Targeting CXCR-4 offers a potential therapeutic strategy for breast cancer.

Purpose:

  • To investigate the impact of shRNA-mediated CXCR-4 gene silencing on the angiogenic potential of human breast cancer cells.

Summary:

  • shRNA-CXCR4 significantly reduced CXCR4 mRNA and protein expression in MCF-7, MDA-MB-231, and MDA-MB-435s breast cancer cell lines.
  • Co-culture experiments demonstrated that CXCR4 gene silencing in breast cancer cells markedly inhibited the ability of human umbilical vein endothelial cells (HUVECs) to form tubular structures.
  • These findings indicate a direct role for CXCR-4 in promoting angiogenesis in breast cancer.

Impact:

  • shRNA-CXCR4 effectively suppresses the angiogenesis-inducing capacity of human breast cancer cells.
  • This study highlights CXCR-4 as a viable molecular target for anti-angiogenic therapy in breast cancer.
  • The results provide a foundation for developing novel therapeutic approaches to inhibit breast cancer progression.

More Related Videos

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs10:32

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 406:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...